Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

ceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fiapta(TM) (iloperidone), is a compound for the treatment of schizophrenia and bipolar disorder, for which Vanda has recently submitted an NDA to the FDA. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a fa
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... beyond, photonics plays an important part in enabling success ... European Commission. Innovation and technology leaders helped bring focus ... thematic sessions during the Photonics21 annual meeting ... a sponsor of the event, held 28 and 29 ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( ... "Bioburden Testing Market by Product , Test, Application & ... their offering. The bioburden testing market is ... Million in 2014, growing at a CAGR of 9.8% ... products, the microbial limit testing market is segmented into ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ... Market by Technology, Application & by Products - Global ... The global genotyping market is expected to reach ... at a CAGR of 22.3% during the forecast period ... be attributed to the availability of a range of ...
(Date:6/2/2015)... June 2, 2015   BioClinica ® , Inc., ... today announced that David Peters , an accomplished ... Vice President and Chief Financial Officer (CFO) and will ... Peters brings more than 25 years of financial and ... has extensive and deep knowledge in all areas of ...
Breaking Biology Technology:Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2
... Mass., Oct. 1 Based on the clinical ... today announced,that the company has expanded its executive ... MA. "The move to Massachusetts,allows us to consolidate ... Geoff Pardo. "It also gives us access to ...
... CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on,endocrine therapy and ... for the Company,s second efficacy trial of ... (BPH), a non-cancerous enlargement of the,prostate, with ...
... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... Va., July 9 For the first time in its ... Liberties (CNIL) has granted approval to a private testing company ... biometric data as part of its efforts to ensure the ... private examination has obtained this permission. , , GMAC ...
... his discovery in Montana of the first trace fossil of ... evidence of more dinosaur burrows this time on the ... to be published this month in Cretaceous Research , ... species, in different hemispheres, and spanned millions of years during ...
... Mental disorders are a global problem and represent one ... world, there are some 500 million people suffering from mental ... one of the leading causes of disease burden. What makes ... neurological disorders is expected to grow for a variety of ...
Cached Biology News:French Authorities Give Sole Approval to GMAT Exam to Collect Biometric Data to Advance Security 2French Authorities Give Sole Approval to GMAT Exam to Collect Biometric Data to Advance Security 3Down Under dinosaur burrow discovery provides climate change clues 2Down Under dinosaur burrow discovery provides climate change clues 322nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 222nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 322nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 422nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 522nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 622nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 722nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 8